Compare HON & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HON | ARGX |
|---|---|---|
| Founded | 1885 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4B | 58.4B |
| IPO Year | 2012 | 2017 |
| Metric | HON | ARGX |
|---|---|---|
| Price | $245.60 | $865.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 19 |
| Target Price | $249.92 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 3.0M | 272.8K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 20.39 | N/A |
| Revenue | ★ $36,529,000,000.00 | N/A |
| Revenue This Year | $6.74 | $44.39 |
| Revenue Next Year | $5.91 | $20.84 |
| P/E Ratio | ★ $11.81 | $33.69 |
| Revenue Growth | ★ 12.92 | N/A |
| 52 Week Low | $186.76 | $631.74 |
| 52 Week High | $252.00 | $953.58 |
| Indicator | HON | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 50.64 |
| Support Level | $234.42 | $822.56 |
| Resistance Level | $242.65 | $881.89 |
| Average True Range (ATR) | 6.93 | 26.32 |
| MACD | 0.47 | -2.43 |
| Stochastic Oscillator | 60.37 | 44.64 |
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.